A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).
about
Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectivesEnter B and W: two new meningococcal vaccine programmes launchedMeningococcal B Vaccination (4CMenB) in Infants and ToddlersPrevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infectionEmerging experience with meningococcal serogroup B protein vaccines.Meningococcal B vaccination: real-world experience and future perspectives.Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.Susceptibility to invasive meningococcal disease: polymorphism of complement system genes and Neisseria meningitidis factor H binding proteinVaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?Effect of antipyretic analgesics on immune responses to vaccination.A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity.Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vacNeisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.The next chapter for group B meningococcal vaccines.The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: a phase 3, open-label, randomized study.Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
P2860
Q26770702-B7530B72-726A-4F30-8F6E-5C32DC6838D0Q26775667-B4F404B8-3CE6-4F89-9938-DC8A749DD52CQ26782285-508060B0-B2A1-4A2E-BDA6-108CCF739EF2Q28080522-51617A77-928B-4229-ACFA-79FB25227865Q30234958-81018742-EA52-4D15-8EF9-38421A3F9DBCQ30249575-2BFB37F5-6A77-4E62-AF3F-F9AC688BE86FQ34316082-8A5C3135-B06D-49AD-AC9B-669D732B2819Q35208975-8BBE6D8E-9E31-4015-BB08-7D390D319CFDQ37130205-8815C874-7818-4F6D-B448-6A4EBEACB077Q37265004-5363109E-72C2-4F7F-92A7-22B076F0AF35Q37483629-3F936F77-5B05-4F64-B533-D50D0A34DBFEQ37713787-BE2B970F-F9FC-4407-831A-4ACC87A78907Q38363907-77A8CEFA-5814-4DBC-9513-22409512BFDBQ38599522-08DC5502-B50E-4348-A0FE-4407F8CF077BQ38677309-E6B53685-BC01-43C7-96D1-511B44AF1307Q40179042-2FAD1769-8A66-4778-8D50-CD2B84176451Q40408137-E1E89645-3517-4341-BED6-2B490E6A4ED0Q50027655-2421F0DB-E0CF-4D79-87C1-4CDC25C3CD08Q54233532-BCA9FF56-63E8-4A25-B11D-F7E697D6E588
P2860
A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 2 randomized controlle ...... occal serogroup B vaccine (I).
@ast
A phase 2 randomized controlle ...... occal serogroup B vaccine (I).
@en
A phase 2 randomized controlle ...... ingococcal serogroup B vaccine
@nl
type
label
A phase 2 randomized controlle ...... occal serogroup B vaccine (I).
@ast
A phase 2 randomized controlle ...... occal serogroup B vaccine (I).
@en
A phase 2 randomized controlle ...... ingococcal serogroup B vaccine
@nl
prefLabel
A phase 2 randomized controlle ...... occal serogroup B vaccine (I).
@ast
A phase 2 randomized controlle ...... occal serogroup B vaccine (I).
@en
A phase 2 randomized controlle ...... ingococcal serogroup B vaccine
@nl
P2093
P2860
P50
P356
P1476
A phase 2 randomized controlle ...... occal serogroup B vaccine (I).
@en
P2093
Daniela Toneatto
Peter M Dull
P2860
P304
P356
10.4161/HV.28666
P577
2014-01-01T00:00:00Z